Potential Drug Targets for LDH: A Potential Breakthrough in Cancer and Neurodegenerative Diseases

Target Name: Lactate Dehydrogenase (LDH)

NCBI ID: P33283

Lactate Dehydrogenase (LDH)

Other Name(s): LDH | LDH5

Potential Drug Targets for LDH: A Potential Breakthrough in Cancer and Neurodegenerative Diseases

Lactate Dehydrogenase (LDH) is a protein that is expressed in various tissues throughout the body, including muscle, heart, liver, and kidney. It is a key enzyme in the metabolism of lactate, which is a byproduct of muscle metabolism. LDH is involved in the final step of the lactate metabolism, which is the conversion of lactate to lactic acid. This conversion is critical for the maintenance of proper muscle function and can be affected by a variety of factors, including muscle exercise, starvation, and certain diseases.

The discovery of LDH as a potential drug target or biomarker has significant implications for the treatment of a variety of conditions. LDH is known to be involved in a number of cellular processes that are important for tissue repair and regeneration, including the regulation of cell growth, cell death, and inflammation. As such, LDH has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key challenges in studying LDH as a potential drug target is its widespread expression in various tissues, which makes it difficult to target specific variations in the gene expression that are associated with the disease. However, recent studies have identified potential targets for LDH that may be able to inhibit its activity and reduce the risk of disease.

One potential target for LDH is the kinase PDGFR-尾, which is a key regulator of cell growth and survival. Activated PDGFR-尾 has been shown to promote the growth and spread of cancer cells, and may also contribute to neurodegenerative diseases. Researchers have identified a potential inhibitor for PDGFR-尾 that could be used to treat a variety of conditions, including cancer, neurodegenerative diseases, and autoimmune disorders.

Another potential target for LDH is the protein p16INK4a, which is a key regulator of cell cycle progression and apoptosis. p16INK4a has been shown to promote the growth and survival of cancer cells, and may also contribute to the development of neurodegenerative diseases. Researchers have identified a potential inhibitor for p16INK4a that could be used to treat a variety of conditions, including cancer, neurodegenerative diseases, and autoimmune disorders.

In addition to its potential as a drug target, LDH is also being studied as a potential biomarker for a variety of diseases. For example, LDH has been shown to be elevated in the blood and urine of patients with cancer, and may be a useful diagnostic tool for this disease. LDH has also been used as a biomarker for a variety of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Overall, the discovery of LDH as a potential drug target or biomarker has significant implications for the treatment of a variety of conditions. Further research is needed to fully understand the role of LDH in these diseases and to develop effective treatments.

Protein Name: Lactate Dehydrogenase (LDH)

The "Lactate Dehydrogenase (LDH) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Lactate Dehydrogenase (LDH) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets